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Angiogenesis is an important contributor to atherosclerotic plaque growth and 
instability. Clinical evidence has linked intraplaque angiogenesis with progressive and 
unstable vascular disease. Proliferating endothelial cells (ECs) can switch their 
metabolism to being highly glycolytic enabling their growth and division in the 
angiogenic process. Recent studies have demonstrated the therapeutic potential of 3-
(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), a commercially available 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) inhibitor, in 
angiogenesis models. For this reason, PFKFB3 inhibitors seem promising compounds 
to be used in promoting plaque stability.  
In the present study, we studied the in vitro effects of the PFKFB3 inhibitor 3PO, and 
of two self-synthesized inhibitors named phenoxindazole analogues (PA-1 and PA-2; 
based on Boyd et al., 2015) on glycolysis, cell proliferation, migration, matrix 
metalloproteinase (MMP) activity and gene expression in ECs. We observed that 
these compounds were able to significantly reduce glycolysis levels in the human 
endothelial cell line EA.hy926. In addition, all three compounds markedly reduced 
endothelial cell migration, proliferation and wound closing capacity which are essential 
for neovessel formation. Moreover, we demonstrated by gelation gel zymography that 
these inhibitors reduce the activity of proMMP-9 and MMP-2 up to 40-50% and 20-
30% compared to control, respectively. Furthermore, real-time PCR results indicate 
that the PA compounds downregulate PFKFB3 gene expression whilst 3PO does not. 
As for markers of migration and angiogenesis, such as ICAM and VEGFR2, these 
were markedly reduced. Finally, gelatinase gene expression was downregulated by 
up to 80%.   
These findings show that PFKFB3 inhibition with PA compounds markedly reduce 
endothelial cell migration, proliferation and gelatinolytic activity concomitant with a 
significant decrease in gelatinase gene expression, EC migration and angiogenesis 
markers. Thus, these compounds have the potential to be tested in an animal model 
of angiogenesis. This project has been funded by the European Union’s Horizon 2020 
Marie Skłodowska-Curie grant (#67552).  
 
 
 
 
